Petros Pharmaceuticals, Inc. (PTPI) Financial Ratios
7 years of historical data (2018–2024) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
N/A
—
5yr avg: 18.13
30Y Low6.1·High33.6
ROE
↓
-571.3%
↑-218% vs avg
5yr avg: -179.9%
30Y Low-162%·High-34%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PTPI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Petros Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $56182 | $79M | $77M | $121M | $907M | $587M | — | — |
| Enterprise Value | $4M | $83M | $72M | $121M | $883M | $578M | — | — |
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — |
| P/S Ratio | 0.01 | 15.46 | 13.17 | 20.12 | 116.06 | 61.45 | — | — |
| P/B Ratio | — | — | 6.15 | 7.22 | 25.50 | 33.63 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PTPI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 16.18 | 12.30 | 20.20 | 113.06 | 60.48 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
PTPI Profitability
Margins and return-on-capital ratios measuring operating efficiency
Petros Pharmaceuticals, Inc. earns an operating margin of -345.8%. Operating margins have compressed from -332.4% to -345.8% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -571.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 76.3% | 76.3% | 72.0% | 61.8% | 79.5% | 57.7% | 18.4% | 25.4% |
| Operating Margin | -345.8% | -345.8% | -233.9% | -332.4% | -231.1% | -180.8% | -124.0% | -54.4% |
| Net Profit Margin | -280.1% | -280.1% | -140.2% | -334.4% | -115.0% | -215.3% | -208.7% | -231.1% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | -571.3% | -571.3% | -55.9% | -76.7% | -33.9% | -161.5% | -1025.9% | — |
| ROA | -64.5% | -64.5% | -24.7% | -40.2% | -13.1% | -32.1% | -51.9% | -48.5% |
| ROIC | -730.9% | -730.9% | -83.1% | -102.1% | -133.7% | -93.4% | -46.5% | -13.4% |
| ROCE | -226.2% | -226.2% | -56.3% | -64.5% | -56.1% | -76.4% | -84.7% | -27.0% |
PTPI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $4M ($7M total debt minus $4M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.66 | 0.59 | 0.01 | 0.45 | 1.71 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | 113.79 |
| Net Debt / Equity | — | — | -0.41 | 0.03 | -0.66 | -0.53 | 1.45 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | 107.05 |
| Debt / FCF | — | — | — | — | — | — | 4.71 | 7.22 |
| Interest Coverage | -31.52 | -31.52 | -25.40 | -33.41 | -48.96 | -5.66 | -1.39 | — |
PTPI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.40x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 2.08x to 0.40x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.40 | 0.40 | 1.89 | 2.08 | 0.99 | 0.62 | 0.29 | 0.41 |
| Quick Ratio | 0.24 | 0.24 | 1.74 | 1.82 | 0.97 | 0.60 | 0.24 | 0.24 |
| Cash Ratio | 0.21 | 0.21 | 1.24 | 1.33 | 0.77 | 0.41 | 0.05 | 0.07 |
| Asset Turnover | — | 0.48 | 0.17 | 0.18 | 0.12 | 0.14 | 0.27 | 0.21 |
| Inventory Turnover | 0.40 | 0.40 | 1.01 | 1.26 | 3.08 | 5.32 | 5.77 | 1.61 |
| Days Sales Outstanding | — | 29.71 | 139.56 | 128.54 | 143.19 | 196.75 | 90.17 | 91.23 |
PTPI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Petros Pharmaceuticals, Inc. returns 100.0% to shareholders annually primarily through dividends.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 100.0% | 100.0% | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 100.0% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $8M | $2M | $2M | $1M | $534068 | $246003 | $100000 |
Peer Comparison
Compare PTPI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PTPIYou | $56182 | -0.0 | — | — | 76.3% | -345.8% | -571.3% | -730.9% | — |
 PRGO | $2B | -1.1 | 7.4 | 11.2 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 HIMS | $7B | 55.4 | 46.5 | 98.7 | 59.3% | 5.2% | 25.2% | 10.7% | 6.4 |
 MNKD | $1B | 176.0 | 29.1 | 79.4 | 82.5% | 11.1% | — | 21.6% | 9.3 |
 LLY | $896B | 41.3 | 29.8 | 99.9 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 PFE | $146B | 18.9 | 10.4 | 16.1 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 JAZZ | $14B | -38.7 | 23.7 | 10.9 | 88.2% | 5.3% | -8.5% | 2.1% | 7.1 |
 INVA | $2B | 6.9 | 6.9 | 8.6 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 SUPN | $3B | -75.8 | 52.6 | 64.5 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 CVS | $116B | 65.1 | 13.4 | 14.8 | 13.8% | 2.6% | 2.3% | 5.0% | 6.2 |
 MCK | $90B | 19.2 | 15.3 | 14.7 | 3.6% | 1.5% | 154.5% | 74.5% | 1.4 |
| Healthcare Median | — | 21.9 | 14.2 | 18.5 | 64.3% | -5.0% | -34.0% | -11.0% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See PTPI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PTPI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PTPI vs PRGO
Side-by-side business, growth, and profitability comparison vs Perrigo Company plc.
Start ComparisonPTPI — Frequently Asked Questions
Quick answers to the most common questions about buying PTPI stock.
What is Petros Pharmaceuticals, Inc.'s P/E ratio?
Petros Pharmaceuticals, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
What is Petros Pharmaceuticals, Inc.'s ROE?
Petros Pharmaceuticals, Inc.'s return on equity (ROE) is -571.3%. The historical average is -82.0%.
Is PTPI stock overvalued?
Based on historical data, Petros Pharmaceuticals, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Petros Pharmaceuticals, Inc.'s dividend yield?
Petros Pharmaceuticals, Inc.'s current dividend yield is 100.00%.
What are Petros Pharmaceuticals, Inc.'s profit margins?
Petros Pharmaceuticals, Inc. has 76.3% gross margin and -345.8% operating margin.